Malaysia Exempts Low-Risk Devices From Conformity Assessment
This article was originally published in PharmAsia News
Executive Summary
The Malaysian government exempted all types of Class A (lowest-risk) devices from conformity assessment requirements as of April 18 to make it easier for companies to bring such products to the market. However, these devices will have to continue complying with other regulatory requirements such as labelling and post-marketing commitments.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.